Skip to main content

Table 4 Crude reporting odds ratio of acute kidney injury with vancomycin combination

From: Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database

Antibiotics or Antibiotic Combinations Total (n) Case (n) Crude RORa (95% CIb)
Vancomycin 5101 723 4.00 (3.69–4.33)
Sulfamethoxazole-Trimethoprim 15,548 938 1.54 (1.44–1.65)
Vancomycin plus Sulfamethoxazole-Trimethoprim 702 76 2.87 (2.26–3.65)
Levofloxacin 11,764 627 1.34 (1.23–1.45)
Vancomycin plus Levofloxacin 563 63 2.98 (2.29–3.87)
Clarithromycin 8040 318 0.97 (0.87–1.09)
Vancomycin plus Clarithromycin 99 11 2.95 (1.58–5.53)
Meropenem 7303 611 2.19 (2.01–2.38)
Vancomycin plus Meropenem 1678 184 2.92 (2.51–3.41)
Fluconazole 4961 398 2.08 (1.87–2.31)
Vancomycin plus Fluconazole 430 53 3.32 (2.49–4.43)
Ceftriaxone 4772 296 1.57 (1.39–1.77)
Vancomycin plus Ceftriaxone 351 44 3.39 (2.47–4.65)
Itraconazole 4354 254 1.47 (1.29–1.67)
Vancomycin plus Itraconazole 305 41 3.67 (2.64–5.10)
Cefazolin 4266 198 1.15 (0.997–1.33)
Vancomycin plus Cefazolin 298 21 1.79 (1.15–2.79)
Cefcapene pivoxil 4262 182 1.05 (0.91–1.22)
Vancomycin plus Cefcapene pivoxil 58 5 2.23 (0.89–5.57)
Minocycline 4066 218 1.34 (1.17–1.54)
Vancomycin plus Minocycline 350 43 3.31 (2.41–4.56)
Micafungin 4008 437 2.93 (2.65–3.24)
Vancomycin plus Micafungin 905 125 3.80 (3.14–4.59)
Cefepime 3971 299 1.94 (1.72–2.18)
Vancomycin plus Cefepime 652 88 3.69 (2.95–4.63)
Tazobactam/piperacillin 3812 483 3.48 (3.16–3.83)
Vancomycin plus Tazobactam/piperacillin 584 119 6.07 (4.96–7.43)
  1. a Reporting Odds Ratio, b Confidence Interval